异恶酰胺在老年类风湿性关节炎患者中的药代动力学。

The pharmacokinetics of isoxicam in elderly patients with rheumatoid arthritis.

作者信息

Grace E M, Rosenfeld J M, Sweeney G D, Buchanan W W

机构信息

McMaster University Health Sciences Center, Chedoke-McMaster Hospitals, Hamilton, Ontario, Canada.

出版信息

Curr Med Res Opin. 1987;10(9):580-91. doi: 10.1185/03007998709112411.

DOI:10.1185/03007998709112411

PMID:3436154

Abstract

Nineteen patients, aged 60 years and over, with rheumatoid arthritis participated in a clinical trial to investigate the pharmacokinetics of isoxicam (a new non-steroidal anti-inflammatory drug) in this age group. The purpose of the study was to determine if the pharmacokinetics are different compared to a younger healthy population. The half-lives were independent of dosage, indicating linearity of pharmacokinetics. Furthermore, the half-lives after repeated dosing were not different from those found after single doses of 400 mg. This shows that there is neither undue accumulation of the drug nor induction of its own metabolism. These results are similar to the results obtained in other centres when isoxicam was administered to healthy subjects between 18 and 32 years.

摘要

19名年龄在60岁及以上的类风湿性关节炎患者参与了一项临床试验，以研究异恶酰胺（一种新型非甾体抗炎药）在该年龄组中的药代动力学。该研究的目的是确定其药代动力学与年轻健康人群相比是否不同。半衰期与剂量无关，表明药代动力学呈线性。此外，重复给药后的半衰期与单次服用400毫克后的半衰期没有差异。这表明该药物既没有过度蓄积，也没有诱导自身代谢。这些结果与其他中心对18至32岁健康受试者使用异恶酰胺时获得的结果相似。